BR112014030910A2 - pó seco para formulação de inalação compreendendo xinafoato de salmeterol, propionato de fluticasona e brometo de tiotrópio e método para preparar o mesmo - Google Patents
pó seco para formulação de inalação compreendendo xinafoato de salmeterol, propionato de fluticasona e brometo de tiotrópio e método para preparar o mesmoInfo
- Publication number
- BR112014030910A2 BR112014030910A2 BR112014030910A BR112014030910A BR112014030910A2 BR 112014030910 A2 BR112014030910 A2 BR 112014030910A2 BR 112014030910 A BR112014030910 A BR 112014030910A BR 112014030910 A BR112014030910 A BR 112014030910A BR 112014030910 A2 BR112014030910 A2 BR 112014030910A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhalation formulation
- dry powder
- same
- fluticasone propionate
- salmeterol xinafoate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
resumo pó seco para a formulação de inalação compreendendo xinafoato de salmeterol, propionato de fluticasona e brometo de tiotrópio e método para preparar o mesmo proporciona-se um pó seco para a formulação de inalação compreendendo xinafoato de salmeterol, propionato de fluticasona e brometo de tiotrópio, como ingredientes farmaceuticamente ativos, e um portador, e uma formulação de inalação compreendendo o mesmo. a formulação de inalação de pó seco inventiva tendo boa uniformidade de teor e mostrando mudanças pequenas nas distribuição de tamanho aerodinâmico de acordo com as mudanças da taxa de fluxo pode liberar eficazmente os ditos ingredientes farmaceuticamente ativos a um sítio alvo na administração e, assim, pode ser útil na prevenção ou tratamento de doenças respiratórias, particularmente asma e copd.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120063665A KR20130140358A (ko) | 2012-06-14 | 2012-06-14 | 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법 |
PCT/KR2013/004880 WO2013187626A1 (en) | 2012-06-14 | 2013-06-03 | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014030910A2 true BR112014030910A2 (pt) | 2017-06-27 |
Family
ID=49758405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014030910A BR112014030910A2 (pt) | 2012-06-14 | 2013-06-03 | pó seco para formulação de inalação compreendendo xinafoato de salmeterol, propionato de fluticasona e brometo de tiotrópio e método para preparar o mesmo |
Country Status (19)
Country | Link |
---|---|
US (2) | US9283232B2 (pt) |
EP (1) | EP2861219A4 (pt) |
JP (1) | JP2015519394A (pt) |
KR (1) | KR20130140358A (pt) |
CN (1) | CN104363895A (pt) |
AU (1) | AU2013275113A1 (pt) |
BR (1) | BR112014030910A2 (pt) |
CA (1) | CA2876283A1 (pt) |
HK (1) | HK1206602A1 (pt) |
IL (1) | IL236198A0 (pt) |
IN (1) | IN2014DN11257A (pt) |
MX (1) | MX2014014755A (pt) |
NZ (1) | NZ703788A (pt) |
PH (1) | PH12014502746A1 (pt) |
RU (1) | RU2015100905A (pt) |
SG (1) | SG11201408292YA (pt) |
TW (1) | TWI565481B (pt) |
WO (1) | WO2013187626A1 (pt) |
ZA (1) | ZA201500208B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015284195B2 (en) | 2014-06-30 | 2019-01-24 | Proveris Scientific Corporation | Sampling apparatus for determining the amount and uniformity of a delivered dose of drug related methods |
WO2016052897A1 (en) * | 2014-09-30 | 2016-04-07 | Hanmi Pharm. Co., Ltd. | Dry powder for inhalation formulation having improved stability of combined active ingredients |
MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
KR20160117069A (ko) * | 2015-03-31 | 2016-10-10 | 한미약품 주식회사 | 복합 활성성분의 안정성이 개선된 흡입용 캡슐제 |
BR112017023351B1 (pt) * | 2015-05-01 | 2023-11-28 | Board Of Regents, The University Of Texas System | Composição farmacêutica e uso da composição farmacêutica |
EP3426329A4 (en) | 2016-03-09 | 2019-11-13 | Proveris Scientific Corporation | METHOD FOR MEASURING THE UNITABILITY OF THE DOSE CONTENT OF INHALATION AND NOSING DEVICES |
CN108066329B (zh) * | 2016-11-11 | 2021-11-16 | 江苏恒瑞医药股份有限公司 | 一种吸入用氟替卡松或其衍生物的微粒的制备方法 |
KR102330428B1 (ko) * | 2019-10-14 | 2021-11-24 | 한미약품 주식회사 | 흡입 제형용 건조 분말 및 이의 제조방법 |
US20230293430A1 (en) * | 2020-06-26 | 2023-09-21 | Mylan Pharma Uk Limited | Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide |
CN115266987B (zh) * | 2022-07-31 | 2023-06-30 | 浙江知一药业有限责任公司 | 治疗呼吸系统疾病的药物组合物 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9322014D0 (en) | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
GB0003935D0 (en) * | 2000-02-08 | 2000-04-12 | King S College London | Formulation for dry powder inhaler |
DE10130371A1 (de) | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
GB0312148D0 (en) | 2003-05-28 | 2003-07-02 | Aventis Pharma Ltd | Stabilized pharmaceutical products |
SE527190C2 (sv) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid |
GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
AU2008217586A1 (en) | 2007-02-19 | 2008-08-28 | Cipla Limited | Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid |
JP2010539182A (ja) * | 2007-09-12 | 2010-12-16 | グラクソ グループ リミテッド | 治療剤の新規組み合わせ |
BRPI0915803A2 (pt) | 2008-07-18 | 2015-11-10 | Prosonix Ltd | processo para aumentar a cristalinidade de pelo menos um material sólido, partícula, composição farmacêutica, e, inalador |
JP5705112B2 (ja) * | 2008-07-30 | 2015-04-22 | エスティーシー.ユーエヌエム | ドライパウダー吸入エアロゾル用の大径キャリア粒子を含む製剤 |
TR201000681A2 (tr) * | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | İnhalasyon yoluyla alınan kuru toz formülasyonları. |
-
2012
- 2012-06-14 KR KR1020120063665A patent/KR20130140358A/ko not_active Application Discontinuation
-
2013
- 2013-06-03 CA CA2876283A patent/CA2876283A1/en not_active Abandoned
- 2013-06-03 RU RU2015100905A patent/RU2015100905A/ru not_active Application Discontinuation
- 2013-06-03 EP EP13804439.1A patent/EP2861219A4/en not_active Withdrawn
- 2013-06-03 CN CN201380030898.0A patent/CN104363895A/zh active Pending
- 2013-06-03 AU AU2013275113A patent/AU2013275113A1/en not_active Abandoned
- 2013-06-03 BR BR112014030910A patent/BR112014030910A2/pt not_active IP Right Cessation
- 2013-06-03 MX MX2014014755A patent/MX2014014755A/es unknown
- 2013-06-03 WO PCT/KR2013/004880 patent/WO2013187626A1/en active Application Filing
- 2013-06-03 SG SG11201408292YA patent/SG11201408292YA/en unknown
- 2013-06-03 US US14/402,548 patent/US9283232B2/en not_active Expired - Fee Related
- 2013-06-03 IN IN11257DEN2014 patent/IN2014DN11257A/en unknown
- 2013-06-03 NZ NZ703788A patent/NZ703788A/en not_active IP Right Cessation
- 2013-06-03 JP JP2015517171A patent/JP2015519394A/ja active Pending
- 2013-06-13 TW TW102120909A patent/TWI565481B/zh not_active IP Right Cessation
-
2014
- 2014-12-09 PH PH12014502746A patent/PH12014502746A1/en unknown
- 2014-12-11 IL IL236198A patent/IL236198A0/en unknown
-
2015
- 2015-01-13 ZA ZA2015/00208A patent/ZA201500208B/en unknown
- 2015-06-22 US US14/746,225 patent/US9549936B2/en not_active Expired - Fee Related
- 2015-07-27 HK HK15107131.8A patent/HK1206602A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US20150283151A1 (en) | 2015-10-08 |
PH12014502746B1 (en) | 2015-02-02 |
WO2013187626A1 (en) | 2013-12-19 |
ZA201500208B (en) | 2016-10-26 |
US9549936B2 (en) | 2017-01-24 |
RU2015100905A (ru) | 2016-08-10 |
JP2015519394A (ja) | 2015-07-09 |
IN2014DN11257A (pt) | 2015-10-09 |
AU2013275113A1 (en) | 2015-02-05 |
US9283232B2 (en) | 2016-03-15 |
CA2876283A1 (en) | 2013-12-19 |
MX2014014755A (es) | 2015-02-24 |
IL236198A0 (en) | 2015-01-29 |
PH12014502746A1 (en) | 2015-02-02 |
EP2861219A1 (en) | 2015-04-22 |
TWI565481B (zh) | 2017-01-11 |
TW201402154A (zh) | 2014-01-16 |
US20150157566A1 (en) | 2015-06-11 |
NZ703788A (en) | 2016-10-28 |
CN104363895A (zh) | 2015-02-18 |
KR20130140358A (ko) | 2013-12-24 |
HK1206602A1 (en) | 2016-01-15 |
SG11201408292YA (en) | 2015-01-29 |
EP2861219A4 (en) | 2015-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014030910A2 (pt) | pó seco para formulação de inalação compreendendo xinafoato de salmeterol, propionato de fluticasona e brometo de tiotrópio e método para preparar o mesmo | |
TN2015000395A1 (en) | Respirable agglomerates of porous carrier particles and micronized drug | |
BR112014027681B8 (pt) | Nanocristais de propionato de fluticasona, composição tópica farmacêutica compreendendo os mesmos, seu uso e método de fabricação | |
CL2016000735A1 (es) | Inhalador de polvo seco que comprende una composición farmacéutica inhalable que comprende propionato de fluticasona, xinafoato de salmeterol y un vehículo de lactosa; uso para tratar asma o epoc. | |
BR112016022598A8 (pt) | composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso | |
BR112013027119A8 (pt) | novos conjugados ligante-droga (adcs) e uso dos mesmos | |
BR112014014262A2 (pt) | nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas. | |
BR112015027017A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas | |
TR201000680A2 (tr) | Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler | |
BR112015006571A2 (pt) | composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados | |
WO2011141929A3 (en) | Aqueous pharmaceutical compositions of fluticasone and olopatadine | |
MY165888A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
BR112014008602A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dosagem medida, métodos para o tratamento de um paciente que sofre ou provavelmente sofre de um distúrbio respiratório, e, método para fabricação de uma composição farmacêutica | |
BR112014016472A2 (pt) | formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo | |
NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
BR112015026053A2 (pt) | composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratamento de um paciente sofrendo ou susceptível a sofrer de um distúrbio respiratório e para fabricação de uma composição farmacêutica | |
BR112014029735A2 (pt) | forma de dosagem e formulação de abediterol | |
WO2011093818A3 (en) | Pharmaceutical compositions comprising salmeterol and fluticasone | |
BR112018072177A2 (pt) | composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta | |
WO2011093811A3 (en) | Pharmaceutical preparations comprising formoterol and fluticasone | |
TR200907914A2 (tr) | Kortlkosteroid içeren kuru toz formunda farmasötik bileşim. | |
WO2011093812A3 (en) | Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form | |
Mix | Camphor/eucalyptus/menthol | |
AR098867A1 (es) | Composición farmacéutica en polvo seco para inhalación | |
BR112017007182A2 (pt) | composição compreendendo ao menos um pó seco obtido por secagem por atomização para aumentar a estabilidade da formulação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |